243 related articles for article (PubMed ID: 14976782)
41. Onset/offset characteristics and intubating conditions of rapacuronium: a comparison with rocuronium.
Zhou TJ; White PF; Chiu JW; Joshi GP; Dullye KK; Duffy LL; Tongier WK
Br J Anaesth; 2000 Aug; 85(2):246-50. PubMed ID: 10992833
[TBL] [Abstract][Full Text] [Related]
42. Neuromuscular recovery following rocuronium bromide single dose in infants.
Rapp HJ; Altenmueller CA; Waschke C
Paediatr Anaesth; 2004 Apr; 14(4):329-35. PubMed ID: 15078379
[TBL] [Abstract][Full Text] [Related]
43. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
Rex C; Wagner S; Spies C; Scholz J; Rietbergen H; Heeringa M; Wulf H
Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873
[TBL] [Abstract][Full Text] [Related]
44. The duration of action of mivacurium is prolonged if preceded by atracurium or vecuronium.
Rautoma P; Meretoja OA; Erkola O; Kalli I
Acta Anaesthesiol Scand; 1995 Oct; 39(7):912-5. PubMed ID: 8848891
[TBL] [Abstract][Full Text] [Related]
45. The neuromuscular effects of 0.6 mg kg(-1) rocuronium in elderly and young adults with or without renal failure.
Kocabas S; Yedicocuklu D; Askar FZ
Eur J Anaesthesiol; 2008 Nov; 25(11):940-6. PubMed ID: 18538050
[TBL] [Abstract][Full Text] [Related]
46. Skin reactions to intradermal neuromuscular blocking agent injections: a randomized multicenter trial in healthy volunteers.
Mertes PM; Moneret-Vautrin DA; Leynadier F; Laxenaire MC
Anesthesiology; 2007 Aug; 107(2):245-52. PubMed ID: 17667568
[TBL] [Abstract][Full Text] [Related]
47. A comparison of rocuronium and vecuronium: the pharmacodynamic, cardiovascular and intra-ocular effects.
Robertson EN; Hull JM; Verbeek AM; Booij LH
Eur J Anaesthesiol Suppl; 1994; 9():116-21. PubMed ID: 7925202
[TBL] [Abstract][Full Text] [Related]
48. Muscle relaxants in paediatric day case surgery.
Meakin GH
Eur J Anaesthesiol Suppl; 2001; 23():47-52. PubMed ID: 11766247
[TBL] [Abstract][Full Text] [Related]
49. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
[TBL] [Abstract][Full Text] [Related]
50. Model-based control of neuromuscular block using mivacurium: design and clinical verification.
Schumacher PM; Stadler KS; Wirz R; Leibundgut D; Pfister CA; Zbinden AM
Eur J Anaesthesiol; 2006 Aug; 23(8):691-9. PubMed ID: 16805935
[TBL] [Abstract][Full Text] [Related]
51. Equi-lasting doses of rocuronium, compared to mivacurium, result in improved neuromuscular blockade in patients undergoing gynecological laparoscopy : [Des doses de durée équivalente de rocuronium, comparé au mivacurium, améliorent la curarisation chez des patientes qui subissent une laparoscopie gynécologique].
Dahaba AA; Schweitzer E; Fitzgerald RD; Schwarz S
Can J Anaesth; 2001 Dec; 48(11):1084-90. PubMed ID: 11744584
[TBL] [Abstract][Full Text] [Related]
52. Precurarization and priming: a theoretical analysis of safety and timing.
Kopman AF; Khan NA; Neuman GG
Anesth Analg; 2001 Nov; 93(5):1253-6. PubMed ID: 11682407
[TBL] [Abstract][Full Text] [Related]
53. The neuromuscular effects of mivacurium in adults with priming technique during nitrous oxide-fentanyl anesthesia: a randomized comparative study with succinylcholine.
Lin SM; Chu YC; Lur JY; Lin SH; Hsiao HT; Lee TY; Tsai SK
Acta Anaesthesiol Sin; 1998 Jun; 36(2):75-80. PubMed ID: 9816716
[TBL] [Abstract][Full Text] [Related]
54. The duration of immobilization causes the changing pharmacodynamics of mivacurium and rocuronium in rabbits.
Kim KS; Jeon JW; Koh MS; Shim JH; Cho SY; Suh JK
Anesth Analg; 2003 Feb; 96(2):438-42, table of contents. PubMed ID: 12538193
[TBL] [Abstract][Full Text] [Related]
55. The onset of rocuronium, but not of vecuronium or mivacurium, is modified by tourniquet inflation.
Audibert G; Donati F
Anesth Analg; 1996 Apr; 82(4):848-53. PubMed ID: 8615509
[TBL] [Abstract][Full Text] [Related]
56. A comparison of the pharmacodynamics of rocuronium and vecuronium during halothane anaesthesia.
Booth MG; Marsh B; Bryden FM; Robertson EN; Baird WL
Anaesthesia; 1992 Oct; 47(10):832-4. PubMed ID: 1359803
[TBL] [Abstract][Full Text] [Related]
57. Rapacuronium: first experience in clinical practice.
Bartkowski RR; Witkowski TA
Eur J Anaesthesiol Suppl; 2001; 23():90-3. PubMed ID: 11766254
[TBL] [Abstract][Full Text] [Related]
58. Neuromuscular effects of rapacuronium in pediatric patients during nitrous oxide-halothane anesthesia: comparison with mivacurium.
Brandom BW; Margolis JO; Bikhazi GB; Ross AK; Ginsberg B; Dear G; Kenaan CA; Eck JB; Woelfel SK; Lloyd ME
Can J Anaesth; 2000 Feb; 47(2):143-9. PubMed ID: 10674508
[TBL] [Abstract][Full Text] [Related]
59. Rocuronium bromide in the ICU: dose finding and pharmacokinetics.
Khuenl-Brady KS; Sparr H; Pühringer F; Agoston S
Eur J Anaesthesiol Suppl; 1995 Sep; 11():79-80. PubMed ID: 8557012
[TBL] [Abstract][Full Text] [Related]
60. The pharmacodynamics of vecuronium in chronic renal failure patients: the impact of different priming doses.
Tarbeeh GA; Othman MM
Ren Fail; 2012; 34(7):827-33. PubMed ID: 22607043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
